StockNews.AI
NAGE
StockNews.AI
42 days

Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen®), as a Potential Parkinson's Disease Therapy in Agreement with Haukeland University Hospital in Bergen, Norway

1. NAGE secured an exclusive license agreement with Haukeland University Hospital. 2. This agreement grants access to proprietary intellectual property related to healthy aging.

2m saved
Insight
Article

FAQ

Why Bullish?

The exclusive licensing deal enhances NAGE's value and strengthens its market position. Historically, exclusive agreements have led to significant revenue increases for biotech firms.

How important is it?

The licensing agreement is likely to fuel innovation and future product offerings, enhancing investor confidence in NAGE’s growth prospects.

Why Long Term?

The potential derived from the proprietary data may yield long-term benefits for NAGE, similar to trends seen with other biotech companies expanding their IP portfolios.

Related Companies

CDXCAMRNPRTA
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced it has entered into a worldwide exclusive commercial license agreement with the Haukeland University Hospital, Bergen, Norway. The agreement secures exclusive rights to a body of proprietary intellectual property, know-how, and data. These data are expected to support future.

Related News